Core Viewpoint - Guangxi Wuzhou Pharmaceutical (Group) Co., Ltd. under Zhongheng Group's "Morning Bell" brand is set to be included in the 2025 China Consumer Brand List, marking a significant milestone in its brand development and recognition as a national quality consumer brand [1][2]. Group 1 - The 2025 China Consumer Brand List is the first national-level consumer brand evaluation led by the Ministry of Industry and Information Technology, aimed at promoting consumption upgrades and cultivating globally recognized brands [1]. - The "Morning Bell" brand, registered in 1986, is associated with the flagship product, Thrombolytic Injection (freeze-dried), which has received multiple awards, including the National Science and Technology Progress Award (Second Class) and the China Patent Excellence Award [1]. - The company emphasizes its development philosophy of "Creating Quality Chinese Medicine to Protect People's Health" and integrates traditional Chinese medicine wisdom with modern pharmaceutical technology [1]. Group 2 - Wuzhou Pharmaceutical is committed to increasing R&D investment through its national-level technology center and collaborative innovation platforms, focusing on modernizing and refining the "Morning Bell" brand products [2]. - The company aims to leverage its inclusion in the China Consumer Brand List to enhance brand development, accelerate innovation-driven growth, and expand its market presence [2].

Group 1 - The Ministry of Industry and Information Technology has announced the 2025 list of China's consumer brands, with Guangxi Wuzhou Pharmaceutical Group Co., Ltd.'s "Morning Bell" brand successfully selected, marking a significant milestone in the brand's development [2] - "Morning Bell" brand, registered in 1986, is associated with the flagship product, Thrombolytic Injection (lyophilized), which is well-regarded in the cardiovascular field due to its advanced freeze-drying technology and comprehensive quality control system [2][3] - The brand has achieved national market coverage across 31 provinces and cities, and has been included in the 2025 list of "China's 500 Most Valuable Brands," with a brand value assessment of 8.216 billion RMB, ranking 489th [3] Group 2 - The company emphasizes a development philosophy of "Creating Good Chinese Medicine for People's Health," focusing on a full industry chain quality control system and integrating traditional Chinese medicine wisdom with modern pharmaceutical technology [3] - The company has invested in research and development, leveraging a national-level technology center and collaborative innovation platforms to enhance the modernization and refinement of "Morning Bell" products, thereby maintaining market advantages [3] - Moving forward, the company aims to deepen brand development, accelerate innovation-driven growth, and expand its national market presence while upholding the essence of traditional medicine [3]